Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma
Antoine Moya‐Plana(Inserm), Caroline Robert(Institut Gustave Roussy), Séverine Le Roy(Université Paris-Saclay), Samy Ammari(Université Paris-Saclay), Jean‐Yves Scoazec(Université Paris-Saclay), Ruth Gabriela Herrera Gómez(Institut Gustave Roussy), Alexander M.M. Eggermont(University Medical Center Utrecht), Stéphan Vagner(Institut Curie), Caroline Rossoni(Institut Gustave Roussy), Isabelle Girault(Inserm), François Janot(Centre Hospitalier Universitaire de Nantes), Laurent Dercle(Memorial Sloan Kettering Cancer Center)
Cited by 89
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k